Bardoloxone methyl may curb kidney disease in type 2 diabetes

06/27/2011 | United Press International · WebMD

Bardoxolone methyl-treated patients with type 2 diabetes had better glomerular filtration rates, a measure of kidney function, compared with those who took a placebo, a study in The New England Journal of Medicine found. Researchers hope the antioxidant drug will delay or prevent the need for dialysis in patients with kidney disease.

View Full Article in:

United Press International · WebMD

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL